ChatGPT could affect your critical thinking skills, study finds
The study is part ofMIT's Media Lab project called"Your Brain on ChatGPT," which is designed to assess the cognitive effect of relying on large language models (LLMs) like ChatGPT when authoring essays.
Dig deeper
Approximately 54 people between the ages of 18 and 39 participated in the study. The individuals were divided into three groups to compose several essays.
RELATED: ChatGPT may be smart enough to graduate law school
One group was allowed to use ChatGPT; the second, Google search; and the third, no AI tools at all. An electroencephalography (EEG) headset was used by the participants while writing to measure the participants' brain activity across 32 regions of the brain.
Each patient drafted essays in three sessions and in a fourth session, some participants were reassigned. The individuals who used ChatGPT transitioned to writing unaided (called "LLM-to-Brain") while some who started the brain-only exercise used the LLM ("Brain-to-LLM")
RELATED: ChatGPT outperformed doctors in diagnostic accuracy, study reveals
The participants' essays were scored by both human teachers and an AI judge, and at the conclusion of the assignment, each person was interviewed following the sessions with researchers asking them about how much they felt they owned their writing.
Researchers determined that of the three groups in the study, the ChatGPT users experienced the lowest brain engagement.
The team concluded that their study has limitations that they document in their report and website and that more research is needed to better understand the use of ChatGPT in various parts of daily life.
The Source
Information for this story was provided by an MIT study, which is part of the MIT Media project "Your Brain on ChatGPT." This story was reported from Washington, D.C.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
4CE Engineering Group Launches with Mission to Modernize Civil Infrastructure Through Strategic Acquisitions
Backed by leading private equity firm Quad-C, new engineering platform aims to unite top regional firms and drive industry-wide progress GREENVILLE, S.C., Aug. 11, 2025 /PRNewswire/ -- Today marks the official launch of 4CE Engineering Group, a new engineering firm formed to modernize the civil infrastructure industry by uniting best-in-class engineering firms across the country. Pronounced "Force," 4CE is backed by middle-market private equity firm Quad-C Management, Inc., and led by industry veteran Wes Kingery, former Chief Operating Officer and Chief Revenue Officer of industry leader Vortex Companies. 4CE Engineering Group is on a mission to bring a new kind of energy to engineering; one rooted in collaboration, growth, and purpose. The group is actively seeking to partner with small to mid-sized firms in the water / wastewater, stormwater, transportation, aviation, and civil infrastructure markets that: Value their people and culture, Are regional leaders aiming to grow without losing control, and Believe in the power of collaboration to move the industry forward. "We built Vortex into the number one brand in trenchless infrastructure, scaling 15X in eight years and expanding the team from 150 to 1400 in that time, resulting in a world class organization," said Wes Kingery, Founder and CEO of 4CE. "Now, we're bringing that same velocity and vision to engineering with a platform that empowers firms to grow without sacrificing who they are." The name 4CE reflects a double meaning: "Force Civil Engineers," a nod to the company's civil focus and bold intent to drive change, and a tribute to Quad-C as well as Wes Kingery's four children. At its core, 4CE represents the strength, energy, and unity required to move the industry forward, connecting asset owners, engineers, contractors, and manufacturers in new ways. "4CE will be more than a holding company - we plan to build a coalition of high-performance firms committed to better outcomes, smarter infrastructure, and long-term impact," said Matt Trotta, Principal at Quad-C. "We're proud to support this effort and the leadership behind it." 4CE's growth strategy centers on acquiring engineering firms with strong regional footprints, cultural alignment, and expertise in core infrastructure disciplines. The firm will provide strategic support, operational resources, and capital investment to help partner firms scale, innovate, and retain their unique identities. About 4CE Engineering Group4CE is an engineering growth platform designed to partner with select civil infrastructure firms to bring about meaningful, sustainable progress. With deep industry roots and financial backing from Quad-C, 4CE empowers firms to scale smartly, serve better, and remain true to their mission. and on LinkedIn. About Quad-CFounded in 1989 and headquartered in Charlottesville, Virginia, Quad-C is a middle market private equity firm focused on investing in well-established services and industrial companies. In its 35-year history, Quad-C has invested over $4 billion of equity across more than 85 companies. The Quad-C team is committed to partnering with entrepreneurs and management teams to accelerate growth and create long-term value. and on LinkedIn. Corporate Contact:Wes KingeryFounder & CEO, 4CE Engineering Group355 S. Main Street, Suite 2288Greenville, SC 29601 Media Contact: Jackie Herrera Email: Phone: 713-791-8284 View original content to download multimedia: SOURCE 4CE Engineering Group Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
26 minutes ago
- Medscape
Implantable Device Shows Promise for Preventing Hypoglycemia
A new minimally invasive device, while still in development, could become a lifesaver for individuals with diabetes who experience hypoglycemia, according to researchers at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts. In a paper published in Nature Biomedical Engineering , Siddharth R. Krishnan, PhD, now an assistant professor of electrical engineering at Stanford University in Stanford, California, and colleagues at MIT described a wireless device implanted into diabetic mice that prevented hypoglycemia. The implant weighs < 2 g and is only 3 cm3 in size; it remains under the skin and releases a powdered version of glucagon automatically when a sensor detects low blood sugar. The researchers simulated hypoglycemia in the mice, and the release of the dry glucagon was triggered wirelessly. Measurements showed a rapid rise in blood glucose soon after the release, with a peak of 30 mg/dL after no more than 15 minutes. A second set of studies replicated conditions that often drive hypoglycemia, such as missed meals and automated infusions from insulin pumps. Similarly, the use of the wireless release of dry glucagon resulted in blood glucose concentrations above the threshold for hypoglycemia (average concentration of 80 mg/dL) within the first hour after the release. An area under the curve analysis over 30 minutes after release showed significant changes in the glucose group compared with the control group who received lactose. 'A Pathway to Emergency Rescue' 'Glucagon is widely administered as an emergency rescue drug for patients suffering acute hypoglycemia, particularly in the context of type 1 diabetes,' corresponding author Daniel Anderson, PhD, a professor at the Koch Institute for Integrative Cancer Research at MIT, told Medscape Medical News . Glucagon's short half-life and low stability in solution has made development of pump systems a challenge, he said. By contrast, 'Dry powder versions of glucagon offer long-term stability but are difficult to deliver,' he said. 'An implantable device that can respond to hypoglycemia and release dry powder glucagon potentially offers a pathway to emergency rescue from hypoglycemia events without the need for patient intervention,' Anderson said. The early impact of the dry power was unexpected, Anderson said. 'The glucagon in our system is a dry powder that we designed to dissolve directly in biofluid, and the timeline for this dissolution and subsequent availability of the drug in circulation was an open question when we started this project,' he noted. 'The fact that we saw biological activity within 5 minutes of drug release was an important result in this context, and not one that we predicted.' Although the device is not ready for human use, the size and longevity are key questions for adoption in clinical practice, Anderson told Medscape Medical News . 'We are working on miniaturizing the device, so it is compatible with minimally invasive insertion techniques, and with a sufficient number of doses to provide protection from acute hypoglycemia for multiple years,' he said. 'So far, we have validated the device in preclinical small animal models.' Simultaneously miniaturizing the system and optimizing the dose and longevity in large animal models are the next steps for research, he added. Unmet Need for Glycemic Control 'Hypoglycemia and fear of hypoglycemia remains major barriers to optimal glycemic control for those with diabetes,' said Andrew Kraftson, MD, a specialist in endocrinology and internal medicine at the University of Michigan, Ann Arbor, Michigan, in an interview. 'Glucagon emergency delivery devices have advanced and become more user friendly but will not work if not available or expired. Liquid glucagon presents numerous challenges and is not yet commercially available for dual hormone insulin pump use,' said Kraftson, who was not involved in the research. 'Dual hormone pumps that are being studied or have been approved in Europe are large/bulky, may require two CGM [continuous glucose monitoring] sensors, and may require glucagon to be refilled more frequently than insulin, so a nonliquid, implantable device could avoid some of the obstacles posed by liquid glucagon,' Kraftson noted. However, more research is needed on the logistics of human implementation of the glucagon delivery device tested in the current study, Kraftson told Medscape Medical News . Questions include how the device would be implanted; how many doses the reservoir would hold; and how often, on average, it would need to be changed, he said. Other factors include how cumbersome this device might be for humans, potential risks for irritation or infection, and options for manual delivery in the event of a malfunctioning CGM or signal challenges in device communication, he said. 'Ideally, glucagon use for patients with diabetes would expand beyond emergency rescue,' Kraftson added. 'Reducing or even holding insulin is sometimes insufficient to avoid hypoglycemia, particularly rapid onset.' 'Additionally, eating carbohydrates to prevent or treat hypoglycemia is not ideal given the risk of subsequent overcorrection/hyperglycemia and weight gain; therefore, more frequent, sensor/algorithm-based use of glucagon can more effectively achieve stable glucose levels and help avoid the 'rollercoaster,'' he said. The small size of the device in the current study may limit its ability to participate in the larger mission of glucose management but could certainly still play an important role in hypoglycemia reduction, he noted. This study was funded by the Leona M. and Harry B. Helmsley Charitable Trust, the National Institutes of Health, a JDRF postdoctoral fellowship, and the National Institute of Biomedical Imaging and Bioengineering. Anderson and several coauthors reported being inventors on a patent application relevant to the technology described in this study but had no other financial conflicts of interest.
CNET
26 minutes ago
- CNET
Limited Time Best Buy Sale Lops Up to 58% Off Chromebook Models, Just in Time for Back-to-School Season
If you've been waiting for a chance to get your hands on a Chromebook but you don't like the prices that are normally involved, then today could be a very good day for you. After all, it's not often a bunch of great options get discounted all at the same time. Best Buy has just kicked off a massive sale that knocks up to 58% off a range of different Chromebook options. It means that you can snag budget options and even more expensive ones with some hefty savings, with prices starting at just $169. These deals won't last for long though, so make sure you grab the one you want quickly. There are a total of 10 on sale at the moment, so we'll quickly cover the cheapest and most expensive options. The Lenovo IdeaPad Slim 3 has a 14-inch screen, 4GB of RAM, and 64GB of storage. It'll get the job done for most low-lift tasks, and it's currently $230 off, dropping it to just $169. On the high end, you've got the Asus ExpertBook CX54 with a 2K, 14-inch screen, 16GB of RAM and a 256GB SSD. This thing'll cover pretty much everything you can do on a Chromebook, and it's $180 off, meaning it's down to $649. There are plenty of options between these two, so it's best to have a look at them with a clear view of your budget and needs. Hey, did you know? CNET Deals texts are free, easy and save you money. Given the wealth of options here, along with the size of some of the discounts, these are easily some of the best Chromebook deals going on at the moment. Make sure you grab the option you want quickly though, as the sale is due to end Sunday, Aug. 17. Why this deal matters With back-to-school season upon us, many parents are looking to upgrade the daily carry of their kids. Chromebooks offer an affordable alternative to regular Windows or Mac laptops, and if the browser-based nature suits the type of work your kids will be doing, these are some of the best offers going right now.
